Characteristics of cirrhosis-associated cryptococcosis first diagnosed after death are not fully known. In a multicenter study, data generated as standard of care was systematically collected in 113 consecutive patients with cirrhosis and cryptococcosis followed for 80 patient-years. The diagnosis of cryptococcosis was first established after death in 15.9% (18/113) of the patients. Compared to cases diagnosed while alive, these patients had higher MELD score (33 vs. 22, P = .029) and higher rate of cryptococcemia (75.0% vs. 41.9%, P = .027). Cases diagnosed after death, in comparison to those diagnosed during 
Introduction
Patients with cirrhosis of the liver are uniquely susceptible to cryptococcosis as a result of cirrhosis-associated defects in host immune defenses. [1] [2] [3] [4] An estimated 21-36%
of the cases of cryptococcosis in non-HIV infected hosts in some series have occurred in cirrhotic patients. [1] [2] [3] [4] Decompensated liver disease was an independent risk factor and increased the risk for cryptococcal meningitis and cryptococcemia by 24-fold. 5 Mortality rates in these patients have ranged between 75% and 81% with cryptococcosis accounting for up to 92% of the deaths. 2, 4, 6 Most cryptococcal disease is considered to be due to reactivation of quiescent or latent foci in the lungs that represent granulomatous response to inhaled basidiospores. 7 Indeed, a previous study documented that a vast majority of the patients with cirrhosis had cryptococcal antibodies prior to transplantation, suggesting evidence of prior infection. 7 Lymphohematogenous spread from a subclinical pulmonary focus in the setting of immune impairment has the potential to lead to extrapulmonary and disseminated disease. It is noteworthy that cryptococcocal disease in patients with cirrhosis often remains clinically silent or undiagnosed and is recognized only at autopsy. A literature review based on case reports and case series documented that the diagnosis was first established after death in 38% (10/26) of the cases. 4 In a multicenter study involving consecutive cases of cryptococcosis in cirrhotic patients occurring over ∼15 years, we observed that in a significant proportion of the cases, the diagnosis was established after death. 8 In this report, we sought to determine the characteristics of cryptococcal disease and assess differences if any, between patients in whom the diagnosis was established before versus after death, with the goals of facilitating timely recognition of cryptococcosis whenever feasible.
Patients and methods
This was a multicenter study involving consecutive patients with cirrhosis of the liver and cryptococcosis at the participating institutions. Data were generated as standard of care at the study sites between January 2000 and March 2014 and collected retrospectively. 8 Variables collected included demographics, underlying liver disease, severity of illness as assessed by the MELD scores, comorbid conditions, manifestations of cryptococcal disease, sites of involvement, antifungal therapy, and patient outcomes. Central nervous system (CNS) disease fungemia, or involvement of two or more noncontiguous organ sites, was regarded as disseminated cryptococcal disease. 10, 11 Decompensated liver disease was defined as
Child-Pugh class B or C end stage liver disease. Details of this cohort in a study focusing on post-transplant outcomes have previously been reported. 8 
Statistical analyses
All statistics were performed using Stata/SE, version 14.0, College Station, TX. Data presented are both descriptive and comparative. For the latter analyses, the data were categorized into the binary variable based on whether cryptococcal disease was diagnosed before or after death. Odds ratios and 95% confidence intervals for factors associated with diagnosis after death were estimated using a logistic model.
Results
The study population comprised 113 cirrhotic patients with cryptococcosis; clinical and demographic characteristics of these patients are shown in Table 1 . Patients were followed until death or up to 9 years after the diagnosis of cryptococcal disease; survivors had a median follow up of 422 days (interquartile range [IQR] 38 to 1189 days). Total follow-up in the study population was 80 patientyears. In all, 52.2% (59/113) had concurrent comorbid conditions that included diabetes mellitus in 30.1% (34/113), malignancy in 15.0% (17/113), and requirement of renal replacement therapy at diagnosis in 14.2% (16/113) ( Table 1) . None had HIV infection. The median MELD score of the patients was 22 (IQR 18-30.5) and a majority (66%) belonged to Child-Pugh class C ( Table 1) .
Characteristics of patients diagnosed while alive versus after death
The diagnosis of cryptococcosis was first established after death in 15.9% (18/113) of the patients with cirrhosis. Of these, 12 had cryptococcemia; in the other 6 patients, samples that yielded the diagnosis were pleural fluid/pulmonary cultures in 3, and ascitic fluid, lung nodule, and autopsy in 1 case each. Patients with cryptococcosis had median MELD (model of end stage liver disease) score of 33 (IQR 21-41) and all except one had decompensated liver disease (ChildPugh class C, 81%, and class B, 13%) ( Table 2 ). Compared to patients who were diagnosed antemortem, those diagnosed after death had higher MELD score (odds ratio 1.06, 95% CI 1.01-1.12; P = .029). Cases diagnosed after death were significantly more likely to present with septic shock (odds ratio 3.42, 95% CI 1.18-9.90; P = .023), and acute respiratory failure requiring mechanical ventilation at admission (odds ratio 8.50, 95% CI 2.74-26.38; P < .001).
Other characteristics including etiology of liver disease, comorbid conditions such as underlying malignancy, diabetes mellitus, and need for renal replacement therapy were not different for patients diagnosed antemortem or after they had died ( Table 2 ). The proportion of patients for whom blood cultures were performed did not differ for cases diagnosed during after death or during life (90.5%, 86/95 vs. 88.9%, 16/18, respectively; P = .83). However, cases diagnosed after death were significantly more likely to have fungemia (75%, 12/16 vs. 41.9%, 36/86; P = .015); the blood culture yielded the organism after death for all 12 cases with fungemia. Among fungemic patients only, the incidence of septic shock did not differ for patients diagnosed after death 58.3% (7/12) and those diagnosed while alive (27.8%, 10/36; P = .08). However, fungemic patients diagnosed after death were significantly more likely to have required ventilatory support than those diagnosed during life (66.7%, 8/12 vs.13.9%, 5/36; P = .0004).
Cases diagnosed after death versus those diagnosed during life were less likely to undergo testing for serum cryptococcal antigen (33% vs. 88%, P < .001) and to have positive antigen when the test was performed (75% vs. 17%, P = .016), respectively ( Table 2) . None of the patients diagnosed after death had CSF analysis performed (0/18) versus 67.3% (64/95) of those diagnosed while alive (P < .001).
Outcomes
Overall mortality rate at 90 days in the study population was 61% (69/113). Mortality rate in patients in whom cryptococcal disease was diagnosed antemortem versus after death was 53.7% (51/95) ( Table 2 ). The time from presentation to death was significantly lower in patients diagnosed after death (median 3 days) compared to patients diagnosed alive but who succumbed to their illness later (median 14 days, P < .001) ( Table 2 ). Only 3 of 113 patients underwent autopsy examination; these included 1 patient diagnosed in whom the diagnosis was first established at autopsy and 2 in whom the diagnosis was known before death.
Discussion
Patients with cirrhosis have defects in antifungal immunity as a result of impaired cell-mediated immunity, phagocytic dysfunction, decreased antibody and immunoglobulins, and complement deficiency. [1] [2] [3] [4] Additionally, novel host-defense defects including, polymorphism in fungal-pathogen sensing pathways and signaling also contribute to the risk of fungal disease in these patients. 12 Observations from our study have implications relevant for the recognition and management of cryptococcosis in cirrhotic patients. The diagnosis of cryptococcal disease was established after death in ∼15% of the patients. These patients had more advanced liver disease and higher rate of cryptococcemia. Whether severity of cirrhosis-associated host defense defects, microbial attributes or enhanced virulence, comorbidities or other unmeasured factors contributed to the risk of disseminated cryptococcosis in the setting of advanced liver disease, remains to be determined. The initial manifestation of cryptococcal disease in 23% (26/113) of the cirrhotic patients was shock. This proportion is similar to that in another report in which 27% (3/11) of the patients with cirrhosis and cryptococcemia had septic shock at presentation. 13 A fulminant presentation with hypotension, septic shock states, and acute respiratory failure are not routinely appreciated manifestation of cryprococcosis. [14] [15] [16] [17] In a cohort of 52 HIV-infected and uninfected patients with cryptococcemia, 8% presented with septic shock. 13 Patients with liver cirrhosis were more likely to present with septic shock and less likely to receive antifungal therapy than all other patients. 13 Indeed, cirrhosis of the liver was the strongest independent predictor of mortality and conferred 16-fold higher risk of death even when controlled for sepsis. 13 An aggressive presentation with acute respiratory distress also carries grave prognosis in patients with cryptococcosis. Of 33 non-HIV infected hosts with cryptococcocal disease, 11 presented with respiratory failure requiring mechanical ventilation within 24 hours of admission; 18 55% of these patients died. Our data show that cirrhotic patients in whom cryptococcosis is diagnosed after death were significantly more likely to have septic shock and acute respiratory failure requiring mechanical ventilation at admission. In all, 64% of the fungemic patients diagnosed after death required mechanical ventilation upon presentation.
Cryptococcus has a unique propensity for the CNS and meningoencephalitis is the most common end-organ manifestations of the yeast. Establishment of CNS disease usually occurs over several weeks (∼2-4 weeks) of clinical illness. 14 CNS involvement therefore typically has subacute progression and may remain subtle or clinically silent unless a lumbar puncture is performed for CSF analysis.
14 In all, 67% of our patients diagnosed while alive underwent CSF examination, and 55.8% had CNS disease documented. On the contrary, CSF analysis was pursued in none of the 18 patients diagnosed after death and CNS disease was documented at autopsy in only one of these cases (Table 2) . However, the incidence of CNS disease in patients who died without CSF analysis may have been underestimated since greater severity of liver disease and resultant coagulopathy may have precluded routine performance of lumbar puncture in patients diagnosed after death. Additionally, stabilization of the patient and management of sepsis at admission in these patients may have taken precedence over invasive diagnostic procedures, such as a lumbar puncture. Nevertheless, it is plausible that the incidence of CNS disease was truly low in patients diagnosed after death and that fulminant sepsis and the rapidity with which these patients succumbed to their illness may not have allowed sufficient time for CNS involvement to occur. This, however, remains to be proven. It may be argued that unusual characteristics, including sepsis and respiratory failure as presenting features of cryptococcosis as opposed to more typical manifestations, such as meningoencephalitis, posed diagnostic challenges for the consideration and timely recognition of this fungal pathogen. Although there was no difference in the proportion of patients diagnosed antemortem or after death for whom the blood cultures had been collected, serum cryptococcal antigen testing was performed in significantly fewer of the latter cases ( Table 2 ). These data show that cryptococcosis was not a routine diagnostic consideration in patients presenting with shock or that there was insufficient opportunity to perform the test given that these patients succumbed rapidly to their illness.
A novel finding of the study is that serum cryptococcal antigen was less likely to be positive in cases diagnosed after death, despite the fact that ∼75% were fungemic (Table 2 ). This finding could be due to absence of precipitation as a result of antigen excess from high fungal load, an entity referred to as the post-zone phenomenon. 19 Alternatively, it is plausible that the fungal load might in fact have been lower in these patients and that the dissemination was in fact a very recent event or had not been going on long enough for to develop a positive serum cryptococcal antigen. Whether newer, more rapid diagnostic tests such as cryptococcal lateral flow assay 20 and other phenotypeindependent identification can facilitate earlier diagnosis of this fungal disease in this host population, remains to be determined. There are limitations of this study that should be acknowledged. The data generated were based on review of routine clinical care and the precise reasons that may have precluded earlier identification of the disease are not known. At the same time, however, these findings highlight the dilemma and challenges that cirrhosis-associated cryptococcosis poses in the real-life clinical settings for care providers. Low autopsy rate in this patient population may have potentially underestimated the overall impact of cryptococcosis. Our sample size, while relatively small, is the largest cohort to our knowledge with cirrhosis of the liver and cryptococcosis. Furthermore, the multicenter design enhances generalizability.
Based on our data, a characteristic profile of cirrhotic patients in whom cryptococcosis was diagnosed after death has emerged. Cryptococcal disease in patients with advanced liver disease had fulminant presentation with high rates of fungemia, manifested with septic shock and acute respiratory failure requiring mechanical ventilation, was less likely to be associated with positive serum cryptococcal antigen and had grave outcome with death occurring rapidly after presentation. Awareness of the unique features of this invasive fungal infection in patients with decompensated liver disease may facilitate early recognition of such cases.
